SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Biofrontera Inc. BFRIW NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Biofrontera Inc. (BFRIW) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.03. It has a SharesGrow Score of 30/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Valuation: BFRIW trades at a trailing Price-to-Earnings (P/E) of -1.1 (S&P 500 average ~25).

Financials: revenue is $42M, +13.4%/yr average growth. Net income is $11M (loss), growing at -997.7%/yr. Net profit margin is -25.3% (negative). Gross margin is 75.8% (+28.8 pp trend).

Balance sheet: total debt is $6M against $10M equity (Debt-to-Equity (D/E) ratio 0.59, moderate). Current ratio is 1.52 (strong liquidity). Debt-to-assets is 21.6%. Total assets: $29M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 50/100 (Partial), Future ?/100 (Fail), Income 10/100 (Fail).

BFRIW SharesGrow Score Overview

40/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 48/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BFRIW

No analyst coverage available for this stock.

BFRIW: +13.4%/yr revenue is, -997.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet BFRIW: Debt-to-Equity (D/E) ratio 0.59 (moderate), Current ratio is 1.52 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

BFRIW: Gross margin is 75.8% (+28.8 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

BFRIW: Net profit margin is -25.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0512-0.0971

Volume32.31K

Avg Volume (30D)4.02K

Market Cap$349.45K

Beta (1Y)0.64

Share Statistics

EPS (TTM)-1.04

Shares Outstanding$10.17M

IPO Date2021-10-29

Employees92

CEOHermann Luebbert

Financial Highlights & Ratios

Revenue (TTM)$41.71M

Gross Profit$31.59M

EBITDA$-10.48M

Net Income$-10.54M

Operating Income$-11.35M

Total Cash$6.39M

Total Debt$6.16M

Net Debt$-231K

Total Assets$28.56M

Price / Earnings (P/E)-0

Price / Sales (P/S)0.01

Analyst Forecast

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS09077D1182

Price Chart

BFRIW

Biofrontera Inc. ↗ · NASDAQ Capital Marke

Healthcare • Drug Manufacturers - Specialty & Generic

0.05 52WK RANGE 0.10

People Also View

Biofrontera Inc.

Inspira Technologies Oxy B.H.N. Ltd.

Bluejay Diagnostics, Inc.

NRx Pharmaceuticals, Inc.

Pasithea Therapeutics Corp.

Eli Lilly and Company

Johnson & Johnson

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message